---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-002543"
form_type: "8-K"
ticker: "CATX"
cik: "0000728387"
company_name: "Perspective Therapeutics, Inc."
filed_at: "2023-02-06T23:59:59+00:00"
generated_at: "2026-06-20T00:37:07.720071+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Isoray closes all-stock merger with Viewpoint; Spoor named CEO, Woods Chair

## Summary
- Completed all-stock merger with Viewpoint; issued 136.5M shares (49% of pro forma) at 3.1642 exchange ratio.
- New CEO Thijs Spoor (ex-Viewpoint CEO) appointed; Lori Woods becomes Chairperson of the Board.
- Woods receives $504K severance, accelerated vesting of 1,007,498 stock options under separation agreement.
- Board expanded to five: Woods (Chair), Spoor, Morich, Williamson, and McCormick.
- Fiscal year changed from June 30 to December 31; transition Form 10-KT to be filed.

## SEC filing metadata
- accession: 0001437749-23-002543
- form_type: 8-K
- ticker: CATX
- cik: 0000728387
- company_name: Perspective Therapeutics, Inc.
- filed_at: 2023-02-06T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 1.02, 5.02, 2.01, 3.02, 5.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/728387/000143774923002543/0001437749-23-002543-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/728387/000143774923002543/isr20230204_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-002543
- JSON: https://secwatch.observer/filing/0001437749-23-002543.json
- Plain text: https://secwatch.observer/filing/0001437749-23-002543.txt

## Key facts
- Executive change
  Frank Morich was appointed as Director at Perspective Therapeutics, Inc..
  - Action: appointed
  - Role: Director
  source text: (iv) Dr. Frank Morich as a director of the Company
  evidence_url: https://www.sec.gov/Archives/edgar/data/728387/000143774923002543/0001437749-23-002543-index.htm
- Executive change
  Alan Hoffmann resigned as Director at Perspective Therapeutics, Inc..
  - Action: resigned
  - Role: Director
  source text: Alan Hoffmann and Dr. Philip Vitale each gave notice of their resignation from the Board of Directors of the Company (the “ Board ”), effective upon the Closing.
  evidence_url: https://www.sec.gov/Archives/edgar/data/728387/000143774923002543/0001437749-23-002543-index.htm
- Executive change
  Lori A. Woods resigned as Chief Executive Officer at Perspective Therapeutics, Inc..
  - Action: resigned
  - Role: Chief Executive Officer
  source text: On February 1, 2023, and effective upon the Closing, Lori A. Woods gave notice of her resignation as the Chief Executive Officer of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/728387/000143774923002543/0001437749-23-002543-index.htm
- Executive change
  Philip Vitale resigned as Director at Perspective Therapeutics, Inc..
  - Action: resigned
  - Role: Director
  source text: Alan Hoffmann and Dr. Philip Vitale each gave notice of their resignation from the Board of Directors of the Company (the “ Board ”), effective upon the Closing.
  evidence_url: https://www.sec.gov/Archives/edgar/data/728387/000143774923002543/0001437749-23-002543-index.htm
- Executive change
  Johan (Thijs) Spoor was appointed as Chief Executive Officer at Perspective Therapeutics, Inc..
  - Action: appointed
  - Role: Chief Executive Officer
  source text: the Board appointed: (i) Johan (Thijs) Spoor as Chief Executive Officer and a director of the Company
  evidence_url: https://www.sec.gov/Archives/edgar/data/728387/000143774923002543/0001437749-23-002543-index.htm
- Executive change
  Robert Froman Williamson, III was appointed as Director at Perspective Therapeutics, Inc..
  - Action: appointed
  - Role: Director
  source text: (iii) Robert Froman Williamson, III as a director of the Company
  evidence_url: https://www.sec.gov/Archives/edgar/data/728387/000143774923002543/0001437749-23-002543-index.htm
- Executive change
  Lori A. Woods was appointed as Chairperson of the Board at Perspective Therapeutics, Inc..
  - Action: appointed
  - Role: Chairperson of the Board
  source text: (ii) Lori A. Woods as Chairperson of the Board
  evidence_url: https://www.sec.gov/Archives/edgar/data/728387/000143774923002543/0001437749-23-002543-index.htm
- Governance Changes
  Perspective Therapeutics, Inc.: The Board approved a change in the Company's fiscal year end from June 30 to December 31, effective immediately (effective 2023-01-31).
  - Change: fiscal year change
  - Effective: 2023-01-31
  source text: On January 31, 2023, the Board approved a change in the fiscal year end of the Company from June 30 to December 31.
  evidence_url: https://www.sec.gov/Archives/edgar/data/728387/000143774923002543/0001437749-23-002543-index.htm
- M&A Transactions
  Perspective Therapeutics, Inc. completed an acquisition involving Viewpoint Molecular Targeting, Inc. (closed 2023-02-03).
  - Action: acquisition
  - Counterparty: Viewpoint Molecular Targeting, Inc.
  - Closing: 2023-02-03
  source text: On February 3, 2023 (the " Closing Date "), the Company completed the merger (the " Closing ") of Isoray Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of the Company (" Merger Sub "), with Viewpoint Molecular Targeting, Inc. (" Viewpoint ") (such transaction being the " Merger ").
  evidence_url: https://www.sec.gov/Archives/edgar/data/728387/000143774923002543/0001437749-23-002543-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.